Robert F. Baltera, Jr.
Robert Baltera, Jr. is a pharmaceutical industry executive who acquired a wealth of business and product management experience during 17 years with biotech pioneer Amgen and 4 years as CEO of Amira Pharmaceuticals, which was acquired by Bristol-Meyers Squibb Company for $475M. . While at Amira, Bob was instrumental in focusing Amira's clinical development efforts and forging key collaborations with partners such as GlaxoSmithKline.
Before becoming Amira's CEO, Bob held a number of senior management positions at Amgen, the last being vice president of corporate and contract manufacturing. He successfully used his collective experience to serve as team leader responsible for the approval of KineretTM in rheumatoid arthritis, a highlight of his many accomplishments while at Amgen. He currently serves on the board of directors of Organovo Holdings, Inc., (ONVO) a publically traded regenerative medicine company. Bob has an MBA from the Anderson School at UCLA and earned his BS in microbiology and a MS in genetics from The Pennsylvania State University.